{"id":"melphalan-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Secondary malignancy"},{"rate":null,"effect":"Infertility"}]},"_chembl":{"chemblId":"CHEMBL1200863","moleculeType":"Small molecule","molecularWeight":"341.67"},"_dailymed":{"setId":"4f83c8f7-4cc0-4219-88d5-7cfddce91198","title":"HEPZATO KIT (MELPHALAN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) KIT [DELCATH SYSTEMS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan belongs to the nitrogen mustard class of alkylating agents. It forms covalent bonds with DNA bases, creating interstrand and intrastrand cross-links that interfere with DNA replication and transcription. This leads to cell cycle arrest and apoptosis, particularly affecting rapidly dividing cancer cells.","oneSentence":"Melphalan is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:12:41.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Light chain myeloma"},{"name":"Waldenström macroglobulinemia"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT05617625","phase":"PHASE2","title":"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"Guenther Koehne","startDate":"2026-06","conditions":"Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease","enrollment":50},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT05504291","phase":"PHASE2","title":"A Study to Give Treatment Inside the Eye to Treat Retinoblastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-11-04","conditions":"Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma","enrollment":26},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT07400328","phase":"PHASE2","title":"Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Oral Mucositis, Stomatitis, Gastrointestinal Mucositis","enrollment":22},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT04681417","phase":"PHASE2, PHASE3","title":"Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2021-03-25","conditions":"Retinoblastoma","enrollment":225},{"nctId":"NCT02866136","phase":"PHASE2","title":"Conservative Treatments of Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2012-02","conditions":"Retinoblastoma, Children, Retinal Neoplasm","enrollment":133},{"nctId":"NCT00114101","phase":"PHASE3","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12-15","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":460},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT03602235","phase":"PHASE1","title":"High Dose Ascorbic Acid for Plasma Cell Disorders","status":"COMPLETED","sponsor":"Christopher Strouse","startDate":"2019-03-05","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT02909036","phase":"PHASE1","title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-09","conditions":"Multiple Myeloma, Amyloidosis","enrollment":46},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT05893654","phase":"PHASE1, PHASE2","title":"Melphalan Chemoreduction for Ocular Melanoma","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital das Clínicas de Ribeirão Preto","startDate":"2021-05-01","conditions":"Uveal Melanoma","enrollment":10},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06815003","phase":"PHASE2","title":"Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-18","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":35},{"nctId":"NCT06996119","phase":"PHASE1","title":"Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-25","conditions":"Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT04690192","phase":"PHASE1, PHASE2","title":"CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-01-01","conditions":"Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT04342572","phase":"PHASE1","title":"Intra-arterial Chemotherapy for Retinoblastoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-11","conditions":"Retinoblastoma","enrollment":5},{"nctId":"NCT03417284","phase":"PHASE1, PHASE2","title":"Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-09","conditions":"Plasma Cell Myeloma","enrollment":62},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT04018937","phase":"PHASE2","title":"Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-03-22","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT01798004","phase":"PHASE1","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-09","conditions":"Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma","enrollment":150},{"nctId":"NCT06425276","phase":"PHASE4","title":"Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation","status":"COMPLETED","sponsor":"CASI Pharmaceuticals (China) Co., Ltd.","startDate":"2020-07-24","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT02728102","phase":"PHASE2","title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-07","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT01190787","phase":"PHASE2","title":"Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01063179","phase":"PHASE3","title":"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":511},{"nctId":"NCT05922384","phase":"NA","title":"Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma","status":"RECRUITING","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-07-05","conditions":"HIV Infections, Lymphoma","enrollment":3},{"nctId":"NCT04649060","phase":"PHASE3","title":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2020-12-21","conditions":"Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma","enrollment":54},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT05438394","phase":"PHASE1","title":"Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-10-13","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT03639610","phase":"PHASE2","title":"PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2018-08-28","conditions":"Renal Impairment, Multiple Myeloma","enrollment":35},{"nctId":"NCT03393611","phase":"PHASE1","title":"CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-11-30","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid","enrollment":14},{"nctId":"NCT02415036","phase":"PHASE2","title":"Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Delcath Systems Inc.","startDate":"2014-06","conditions":"Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT02716805","phase":"PHASE1","title":"Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-12-13","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT03555032","phase":"PHASE1, PHASE2","title":"TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2018-06-26","conditions":"Melanoma and Sarcoma","enrollment":15},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04799002","phase":"PHASE3","title":"Topotecan and Melphalan for Retinoblastoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-03-11","conditions":"Retinoblastoma, Chemotherapy Effect","enrollment":50},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":"Diffuse Large Cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT02544425","phase":"PHASE2","title":"VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02-21","conditions":"Extranodal NK-T-Cell Lymphoma","enrollment":27},{"nctId":"NCT01637766","phase":"PHASE1","title":"Intra-arterial Chemotherapy for Spinal Metastases","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-04","conditions":"Spinal Diseases, Spinal Metastases, Spinal Tumors","enrollment":12},{"nctId":"NCT03003728","phase":"PHASE2","title":"2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2019-11-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01660633","phase":"PHASE2","title":"Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":61},{"nctId":"NCT01383759","phase":"NA","title":"Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-06-24","conditions":"Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD)","enrollment":20},{"nctId":"NCT00925782","phase":"PHASE2","title":"PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-01","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT01818752","phase":"PHASE3","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-08","conditions":"Multiple Myeloma","enrollment":955},{"nctId":"NCT04008888","phase":"NA","title":"a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-01-05","conditions":"Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma","enrollment":50},{"nctId":"NCT01688401","phase":"PHASE1","title":"Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-08","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG)","enrollment":3},{"nctId":"NCT01293539","phase":"PHASE2","title":"Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-03","conditions":"Retinoblastoma","enrollment":10},{"nctId":"NCT02669615","phase":"PHASE2","title":"Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2016-11-01","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT03687463","phase":"","title":"Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia","status":"UNKNOWN","sponsor":"Capital Research Institute of Pediatrics","startDate":"2015-04-10","conditions":"Hematopoietic System--Cancer","enrollment":6},{"nctId":"NCT00385788","phase":"PHASE2","title":"Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-07","conditions":"Hodgkin's Disease","enrollment":52},{"nctId":"NCT01969435","phase":"PHASE2","title":"Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-03-19","conditions":"Hodgkin Disease, Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT02406508","phase":"PHASE2","title":"Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC","status":"WITHDRAWN","sponsor":"Delcath Systems Inc.","startDate":"2014-10","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT00349778","phase":"PHASE2","title":"High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Multiple Myeloma","enrollment":102},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT00083915","phase":"PHASE3","title":"DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-06","conditions":"Multiple Myeloma","enrollment":97},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT02961816","phase":"PHASE2","title":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00857519","phase":"NA","title":"A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2009-01","conditions":"Retinoblastoma","enrollment":10},{"nctId":"NCT00906113","phase":"PHASE1, PHASE2","title":"Intra-arterial Chemotherapy for Children With Retinoblastoma","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2011-06","conditions":"Retinoblastoma","enrollment":10},{"nctId":"NCT00406978","phase":"PHASE1, PHASE2","title":"Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Silvio Aime","startDate":"2006-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT01558960","phase":"NA","title":"Intravitreal Injections of Melphalan for Retinoblastoma","status":"TERMINATED","sponsor":"Hadassah Medical Organization","startDate":"2012-03","conditions":"Retinoblastoma","enrollment":10},{"nctId":"NCT00434161","phase":"PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":281},{"nctId":"NCT00949039","phase":"PHASE3","title":"Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-02","conditions":"Gynaecologic or Digestive Pelvic Cancer","enrollment":101},{"nctId":"NCT00911859","phase":"PHASE2","title":"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-06","conditions":"Multiple Myeloma","enrollment":118},{"nctId":"NCT01130194","phase":"PHASE2","title":"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2006-07","conditions":"Follicular Lymphoma","enrollment":29},{"nctId":"NCT00507416","phase":"PHASE3","title":"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":502},{"nctId":"NCT01068301","phase":"PHASE1","title":"A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-05","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT00003789","phase":"PHASE3","title":"Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-03","conditions":"Recurrent Melanoma, Stage III Melanoma","enrollment":216},{"nctId":"NCT01572688","phase":"NA","title":"Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma","status":"UNKNOWN","sponsor":"Shandong Lanjin Pharmaceuticals Co.,Ltd","startDate":"2011-11","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT01134484","phase":"PHASE3","title":"VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)","status":"UNKNOWN","sponsor":"Michele Cavo","startDate":"2006-05","conditions":"Multiple Myeloma","enrollment":480},{"nctId":"NCT00417911","phase":"PHASE3","title":"Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients","status":"COMPLETED","sponsor":"Nordic Myeloma Study Group","startDate":"2005-12","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT00901238","phase":"PHASE1, PHASE2","title":"Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2006-05","conditions":"Retinoblastoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intra-arterial chemotherapy","Chemoreduction"],"phase":"marketed","status":"active","brandName":"Melphalan Injection","genericName":"Melphalan Injection","companyName":"Hospital das Clínicas de Ribeirão Preto","companyId":"hospital-das-cl-nicas-de-ribeir-o-preto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Melphalan is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death. Used for Multiple myeloma, Light chain myeloma, Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}